Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Kidney symbols : GLAXF save search
Kidney Transplantation Therapeutics Market 2023; USD 643.15 million Growth Expected between 2023 and 2028, Rising prevalence of CKD and renal impairments to boost growth - Technavio
Published: 2024-01-29 (Crawled : 18:00) - prnewswire.com
ALPMF | $9.48 1.7K
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: 0.0%
GLAXF | $20.2 510
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -1.15%
ALPMY | $9.2715 500K
|
Manufacturing
|
| O: -3.53%
H: 3.49%
C: 3.4%
NVS | $93.29 -1.19% 530K
|
Health Technology
|
| O: -0.59%
H: 0.49%
C: 0.41%
GSK | $39.935 -1.4% 900K
|
Health Technology
|
| O: 0.26%
H: 0.13%
C: -0.18%
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: 0.19%
H: 0.46%
C: 0.43%
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
kidney renal expected million therapeutics growth market
Kidney stones market size to grow by USD 566.78 million between 2022 and 2027; Growth driven by rising incidence of urolithiasis - Technavio
Published: 2023-03-30 (Crawled : 03:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: -1.99%
H: 0.0%
C: 0.0%
GSK | $39.935 -1.4% 900K
|
Health Technology
|
| O: 0.0%
H: 0.65%
C: 0.6%
kidney growth market
Kidney Stones Market Size to Grow by USD 416.09 Mn | Growing Popularity of Digital Flexible Ureteroscopes to Boost Growth | Technavio
Published: 2022-01-25 (Crawled : 05:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 2.24%
H: 0.09%
C: 0.09%
GSK | $39.935 -1.4% 900K
|
Health Technology
|
| O: -0.83%
H: 1.16%
C: 0.82%
BHC | $8.515 -1.33% 380K
|
Health Technology
|
| O: -1.22%
H: 1.69%
C: 0.0%
growing growth kidney stones kidney
Global End Stage Renal Disease Market 2021-2027: Low Maintenance Dialysis Equipment and Artificial Kidneys are Expected to Drive Market Growth
Published: 2022-01-11 (Crawled : 17:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: 0.0%
SNYNF | $92.966 630
|
Health Technology
|
| O: -3.41%
H: 5.99%
C: 1.1%
NVS | $93.29 -1.19% 530K
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
MDT | $79.3 -1.16% 2.4M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: 0.0%
GSK | $39.935 -1.4% 900K
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
BMY | $48.35 -0.33% 2.1M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: 0.0%
AMGN | $264.99 -0.2% 410K
|
Health Technology
|
| O: 0.71%
H: 0.0%
C: 0.0%
kidney disease dialysis
GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease
Published: 2021-11-05 (Crawled : 22:00) - biospace.com/
GLAXF | $20.2 510
|
Health Technology
|
| O: 3.11%
H: 0.0%
C: 0.0%
GSK | $39.935 -1.4% 900K
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
disease positive kidney
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
PRSO | $1.79 40.95% 38M
|
Manufacturing
MCBC | $13.795 38.92% 820K
|
Finance
BTTR | $6.86 34.51% 5.2M
|
Manufacturing
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.